Table 3.
Up to 12 Week Assessments adjusting for treatment arm and sum of baseline tumor measurements.
| Study | Metric | HR2 | AIC3 | Chi-Square | P-Value | C-Index |
|---|---|---|---|---|---|---|
| N0026 | Best TriTR @ 12 wks1: | |||||
| Stable | 1.29 | 805.3 | 31.2 | <.0001 | 0.67 | |
| Progression | 3.71 | |||||
|
| ||||||
| TriTR @ 12 weks1 | ||||||
| Stable | 1.12 | 807.0 | 29.5 | <.0001 | 0.67 | |
| Progression | 2.58 | |||||
|
| ||||||
| Confirmed Response | 3.67 | 815.4 | 19.1 | 0.0003 | 0.65 | |
|
| ||||||
| TSM | 1.44 | 809.0 | 15.9 | 0.0012 | 0.64 | |
|
| ||||||
| ASM | 3.91 | 799.0 | 25.9 | <.0001 | 0.66 | |
|
| ||||||
| RCB | 1.92 | 807.0 | 17.9 | 0.0005 | 0.65 | |
|
| ||||||
| ARCB | 9.40 | 805.1 | 19.8 | 0.0002 | 0.65 | |
|
| ||||||
| N9741 | Best TriTR @ 12 wks1: | |||||
| Stable | 1.40 | 12590.5 | 201.9 | <.0001 | 0.63 | |
| Progression | 3.71 | |||||
|
| ||||||
| TriTR @ 12 weks1 : | ||||||
| Stable | 1.41 | 11872.0 | 198.4 | <.0001 | 0.64 | |
| Progression | 3.37 | |||||
|
| ||||||
| Confirmed Response | 1.37 | 12699.0 | 91.3 | <.0001 | 0.59 | |
|
| ||||||
| TSM | 1.39 | 12055.7 | 112.1 | <.0001 | 0.60 | |
|
| ||||||
| ASM | 1.76 | 12026.6 | 141.2 | <.0001 | 0.61 | |
|
| ||||||
| RCB | 1.24 | 12055.4 | 112.4 | <.0001 | 0.61 | |
|
| ||||||
| ARCB | 3.99 | 12029.2 | 138.6 | <.0001 | 0.62 | |
|
| ||||||
| N9841 | Best TriTR @ 12 wks1: | |||||
| Stable | 1.26 | 3017.7 | 81.7 | <.0001 | 0.66 | |
| Progression | 3.42 | |||||
|
| ||||||
| TriTR @ 12 weks1 : | ||||||
| Stable | 1.30 | 3005.2 | 105.8 | <.0001 | 0.69 | |
| Progression | 3.77 | |||||
|
| ||||||
| Confirmed Response | 1.15 | 3028.6 | 34.0 | <.0001 | 0.61 | |
|
| ||||||
| TSM | 1.18 | 3004.8 | 34.7 | <.0001 | 0.60 | |
|
| ||||||
| ASM | 1.70 | 2995.8 | 43.6 | <.0001 | 0.62 | |
|
| ||||||
| RCB | 1.55 | 3058.4 | 50.6 | <.0001 | 0.64 | |
|
| ||||||
| ARCB | 4.28 | 2987.3 | 52.2 | <.0001 | 0.64 | |
1
Reference CR/PR
2
HR: Hazard Ratio for 1 unit change in metric
3
Akaike Information Criteria